User:Mr. Ibrahem/Safinamide
Clinical data | |
---|---|
Trade names | Xadago, Onstryv, others |
Other names | EMD-1195686, PNU-15774E; (2S)-2-[[4-[(3-fluorophenyl)methoxy]phenyl] methylamino]propanamide |
AHFS/Drugs.com | Monograph |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
Drug class | Monoamine oxidase inhibitor[2] |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 95% |
Protein binding | 88–90% |
Metabolism | Amidases, glucuronidation |
Elimination half-life | 20–30 hrs |
Excretion | 76% Kidney, 1.5% faeces |
Identifiers | |
| |
Chemical and physical data | |
Formula | C17H19FN2O2 |
Molar mass | 302.349 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Safinamide, sold under the brand name Xadago among others, is a medication used as an add-on treatment for Parkinson's disease with off episodes.[3] Specifically it is used together with levodopa-carbidopa.[3] It is taken by mouth.[3]
Common side effects include trouble sleeping, difficulty controlling movements, sleepiness, dizziness, headache, cataracts, and low blood pressure with standing.[2] Other side effects may include high blood pressure, serotonin syndrome, sudden onset of sleep, an urge to gamble, and hallucinations.[3] is an inhibitor of monoamine oxidase B and therefore increases levels of dopamine.[2]
Safinamide was approved for medical use in Europe in 2015,[2] the United States in 2017,[3] and Canada in 2019.[5] In the United Kingdom a month of medication costs the NHS about £70 as of 2021.[4] In the United States this amount costs about 1,000 USD.[6]
References[edit]
- ^ "Summary of the risk management plan (RMP) for Xadago (safinamide)" (PDF). European Medicines Agency. January 2015. Archived (PDF) from the original on 2017-03-29. Retrieved 2021-08-04.
- ^ a b c d e "Xadago". Archived from the original on 6 March 2021. Retrieved 10 October 2021.
- ^ a b c d e f g "Safinamide Monograph for Professionals". Drugs.com. Archived from the original on 5 October 2021. Retrieved 10 October 2021.
- ^ a b BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 447. ISBN 978-0-85711-369-6.
{{cite book}}
: CS1 maint: date format (link) - ^ Government of Canada, Health Canada (2012-04-25). "Drug Product Database Online Query". health-products.canada.ca. Archived from the original on 2021-08-29. Retrieved 2019-07-21.
- ^ "Xadago Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 17 January 2021. Retrieved 10 October 2021.